AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7166146 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure group
Number of subjects: 0
Study 7166146 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic subjects
Number of subjects: 0
Study 7166146 — intervention group
Group type: EXPERIMENTAL
Intervention: White subjects
Number of subjects: 0
Study 30672067 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG restabilization with an induction dose of 2 g/kg bodyweight (bw) IgPro10 (Privigen) and maintenance doses of 1 g/kg bw every 3 weeks for up to 13 weeks
Number of subjects: 245
Study 30672067 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG restabilization
Number of subjects: 245
Study 30672067 — intervention group
Group type: COMPARATOR
Intervention: IVIG withdrawal
Number of subjects: 245
Study 27687805 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 72
Study 27687805 — intervention group
Group type: COMPARATOR
Intervention: Posterior Approach (PA)
Number of subjects: 72
Study 27687805 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DAA and PA)
Number of subjects: 72
Study 27399131 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (ticagrelor and apixaban)
Number of subjects: 40
Study 27399131 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (ticagrelor and apixaban with acetylsalicylic acid)
Number of subjects: 40
Study 24288164 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive condition (candidates presented with reference to their strengths)
Number of subjects: 80
Study 24288164 — intervention group
Group type: COMPARATOR
Intervention: Standard condition (candidates presented by referring to the disability they presented)
Number of subjects: 80
Study 23082133 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg daily)
Number of subjects: 37
Study 23082133 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (20 mg daily)
Number of subjects: 37
Study 20715300 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (30‐45 mg/day)
Number of subjects: 60
Study 20715300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17383923 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dorsal ramus block
Number of subjects: 14
Study 17383923 — intervention group
Group type: COMPARATOR
Intervention: Trigger point injection
Number of subjects: 14
Study 16264159 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-visit program (n = 1716)
Number of subjects: 3521
Study 16264159 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 1805)
Number of subjects: 3521
Study 12416546 — intervention group
Group type: EXPERIMENTAL
Intervention: Local chemotherapy with cisplatin-depot (CDDP-D)
Number of subjects: 38
Study 12416546 — intervention group
Group type: COMPARATOR
Intervention: Subtotal tumor ablation without CDDP-D implantation (Control Group B)
Number of subjects: 38
Study 10451136 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg x kg(‐1) p.o. 30 min before anesthesia)
Number of subjects: 60
Study 10451136 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 60
Study 7784720 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose epinephrine (1 mg)
Number of subjects: 536
Study 7784720 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (5 mg)
Number of subjects: 536
Study 1315346 — intervention group
Group type: COMPARATOR
Intervention: NaF rinse (12 mmol/L)
Number of subjects: 51
Study 1315346 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-solution F rinse (12 mmol/L)
Number of subjects: 51
Study 1315346 — intervention group
Group type: COMPARATOR
Intervention: Control group (pH 7 remineralizing solution)
Number of subjects: 51
Study 4062049 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) load (920 calories)
Number of subjects: 15
Study 4062049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31281343 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day)
Number of subjects: 7
Study 31281343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29302655 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy for iron reduction
Number of subjects: 1277
Study 26476267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral-Based Physical Therapy (CBPT)
Number of subjects: 86
Study 26476267 — intervention group
Group type: COMPARATOR
Intervention: Education program
Number of subjects: 86
Study 26577091 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care practice support (comprehensive evidence-based quality improvement strategy involving practice facilitation, academic detailing, technology support, and regional learning collaboratives)
Number of subjects: 900000
Study 26577091 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care practice support
Number of subjects: 900000
Study 23730856 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based stroke nursing intervention (three 2-hour sessions per week for 8 weeks)
Number of subjects: 127
Study 23730856 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based stroke nursing intervention
Number of subjects: 127
Study 23730856 — intervention group
Group type: COMPARATOR
Intervention: Normal care group (general stroke education programme)
Number of subjects: 127
Study 21156862 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference mind-set priming
Number of subjects: 0
Study 21156862 — intervention group
Group type: COMPARATOR
Intervention: Mentalizing about out-group targets
Number of subjects: 0
Study 21156862 — intervention group
Group type: COMPARATOR
Intervention: Communication with interaction partners of different minimal-group membership
Number of subjects: 0
Study 18815727 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1,000 mg - Caffeine 130 mg (PCF)
Number of subjects: 0
Study 18815727 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg (NAP)
Number of subjects: 0
Study 18815727 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 0
Study 16807444 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 300 mg/m(2) administered during 1 h infusion
Number of subjects: 20
Study 16807444 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 300 mg/m(2) administered during 2 h infusion
Number of subjects: 20
Study 16807444 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 300 mg/m(2) administered during 3 h infusion
Number of subjects: 20
Study 16807444 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1000 mg/m(2) administered during 30 min infusion
Number of subjects: 20
Study 16807444 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 20
Study 12669262 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine-pyruvate (Cr(pyr), 2 x 3.5 g x d‐1)
Number of subjects: 14
Study 12669262 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14
Study 12669262 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine-pyruvate (Cr(pyr))
Number of subjects: 14
Study 11854983 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation intervention (7-muscle group), home practice with audiocassette tapes and diaries
Number of subjects: 43
Study 11854983 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 minutes of relaxation)
Number of subjects: 43
Study 9104521 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF)
Number of subjects: 130
Study 9104521 — intervention group
Group type: EXPERIMENTAL
Intervention: Double burst stimulation 3.3 (DBS3.3)
Number of subjects: 130
Study 9104521 — intervention group
Group type: EXPERIMENTAL
Intervention: Double burst stimulation 3.2 (DBS3.2)
Number of subjects: 130
Study 7960690 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise training (45 min, 3 times weekly for 12 weeks)
Number of subjects: 40
Study 7960690 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued exercise at varying levels at home during 1 year of follow-up
Number of subjects: 40
Study 7960690 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in lifestyle)
Number of subjects: 40
Study 2884861 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (mean dosage 6.9 mg, range 1 to 16)
Number of subjects: 104
Study 2884861 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) (mean dosage 84.6 mg, range 25 to 100)
Number of subjects: 104
Study 2884861 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 104
Study 2884861 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 104
Study 29803985 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily
Number of subjects: 12000
Study 29803985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12000
Study 27160933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioxtra® toothpaste with salivary enzymes, essential oils, proteins and colostrum extract
Number of subjects: 64
Study 27160933 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste without menthol
Number of subjects: 64
Study 27160933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioxtra® toothpaste
Number of subjects: 64
Study 25359394 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting stent (Zilver® PTX®)
Number of subjects: 186
Study 25359394 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (Misago® RX)
Number of subjects: 186
Study 21900842 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 kcal·kg⁻¹·wk⁻¹ exercise training at 50% of aerobic capacity
Number of subjects: 419
Study 21900842 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 419
Study 20733211 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming condition (scrambled sentence task)
Number of subjects: 64
Study 20733211 — intervention group
Group type: COMPARATOR
Intervention: Skill-focused condition
Number of subjects: 64
Study 20733211 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 64
Study 20733211 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive priming condition
Number of subjects: 64
Study 20733211 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral priming condition
Number of subjects: 64
Study 20733211 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative priming condition
Number of subjects: 64
Study 17593858 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine and 1.0% lidocaine (ropi‐lido group; n=146)
Number of subjects: 287
Study 17593858 — intervention group
Group type: COMPARATOR
Intervention: 1.0% lidocaine alone (placebo‐lido group; n=141)
Number of subjects: 287
Study 15716697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 124
Study 15716697 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 124
Study 12237201 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-lignocaine (20% magnesium sulphate 500 mg + lignocaine 1% 75 mg)
Number of subjects: 49
Study 12237201 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine alone (1% 75 mg)
Number of subjects: 49
Study 8009327 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional restoration treatment at two clinics
Number of subjects: 542
Study 8009327 — intervention group
Group type: COMPARATOR
Intervention: Control group (no functional restoration treatment)
Number of subjects: 542
Study 8009327 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional restoration treatment
Number of subjects: 542
Study 3191660 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 8
Study 31172940 — intervention group
Group type: EXPERIMENTAL
Intervention: UOVO rehabilitation tool
Number of subjects: 1
Study 28296471 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy with mucosal biopsies
Number of subjects: 278
Study 26087107 — intervention group
Group type: EXPERIMENTAL
Intervention: Hange-Shashin-To (HST) 5.0 g mixed with jelly
Number of subjects: 0
Study 26087107 — intervention group
Group type: COMPARATOR
Intervention: Placebo (jelly only)
Number of subjects: 0
Study 23618760 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3 (one sachet twice daily for the length of the antibiotics course and for seven days thereafter)
Number of subjects: 229
Study 23618760 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one sachet twice daily for the length of the antibiotics course and for seven days thereafter)
Number of subjects: 229
Study 21747089 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR-D tumors
Number of subjects: 1852
Study 21747089 — intervention group
Group type: COMPARATOR
Intervention: MMR intact tumors with 18q intact
Number of subjects: 1852
Study 19164269 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise alone (EX)
Number of subjects: 24
Study 19164269 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise combined with moderate caloric restriction (EX + CR)
Number of subjects: 24
Study 16778264 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 mcg qd for children < 11 years old and 400 mcg qd for others)
Number of subjects: 7165
Study 16778264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7165
Study 15117980 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² intravenously (i.v.) day 1 with vitamin B12, folic acid, and dexamethasone
Number of subjects: 571
Study 15117980 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m² i.v. day 1 with dexamethasone
Number of subjects: 571
Study 11881188 — intervention group
Group type: EXPERIMENTAL
Intervention: Amixine
Number of subjects: 0
Study 11881188 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 9623901 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioerodible tetracycline gel
Number of subjects: 18
Study 9623901 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 18
Study 8188838 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable osteosynthesis material
Number of subjects: 50
Study 8188838 — intervention group
Group type: COMPARATOR
Intervention: Metal pin fixation
Number of subjects: 50
Study 2492674 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms levo-thyroxine (LT4)
Number of subjects: 20
Study 2492674 — intervention group
Group type: COMPARATOR
Intervention: Combination of 100 micrograms LT4 and 100 micrograms iodide
Number of subjects: 20
Study 824567 — intervention group
Group type: EXPERIMENTAL
Intervention: Eterobarb
Number of subjects: 27
Study 824567 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 27
Study 31260374 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) treatment
Number of subjects: 1759
Study 31260374 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) treatment
Number of subjects: 1759
Study 31260374 — intervention group
Group type: EXPERIMENTAL
Intervention: Viremia
Number of subjects: 1759
Study 28592515 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine (5 or 10 g l-lysine)
Number of subjects: 12
Study 28592515 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 12
Study 26010632 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone supplement (100 mg of total isoflavones, n=193)
Number of subjects: 386
Study 26010632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=193)
Number of subjects: 386
Study 26010632 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone supplement
Number of subjects: 386
Study 26010632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study 23495124 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + BTB
Number of subjects: 58
Study 23495124 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 58
Study 21900836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 IV, gemcitabine 1500 mg/m2 IV, and bevacizumab 10 mg/kg IV (days 1 and 15 of 28‐day cycles)
Number of subjects: 110
Study 21900836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 IV, carboplatin AUC=5 IV, and bevacizumab 15 mg/kg IV (day 1 of 21‐day cycles)
Number of subjects: 110
Study 19328723 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours of bed rest after angiography
Number of subjects: 195
Study 19328723 — intervention group
Group type: COMPARATOR
Intervention: 4 hours of bed rest after angiography
Number of subjects: 195
Study 19328723 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-arm 2-hour bed rest trial
Number of subjects: 195
Study 19328723 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall procedures
Number of subjects: 195
Study 19328723 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with platelet counts < 100 x 10(9)/L
Number of subjects: 195
Study 17662568 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay educators in asthma self-management programme
Number of subjects: 8
Study 15166883 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD) patients
Number of subjects: 56
Study 15166883 — intervention group
Group type: EXPERIMENTAL
Intervention: Senile dementia of Alzheimer type (SDAT) patients
Number of subjects: 56
Study 15166883 — intervention group
Group type: COMPARATOR
Intervention: Other types of dementia patients
Number of subjects: 56
Study 11668655 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetoencephalography (MEG) with spatial filtering technique
Number of subjects: 15
Study 9630024 — intervention group
Group type: EXPERIMENTAL
Intervention: Static exercise
Number of subjects: 11
Study 9630024 — intervention group
Group type: COMPARATOR
Intervention: Dynamic exercise
Number of subjects: 11
Study 8202906 — intervention group
Group type: EXPERIMENTAL
Intervention: Oilseed rape area
Number of subjects: 2000
Study 8202906 — intervention group
Group type: COMPARATOR
Intervention: Non-oilseed rape area
Number of subjects: 2000
Study 2720578 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine sulfate preparation (MS Contin tablets) administered every 12 hours
Number of subjects: 17
Study 2720578 — intervention group
Group type: COMPARATOR
Intervention: Morphine oral solution (MOS) administered every 4 hours
Number of subjects: 17
Study 2720578 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MSC and MOS
Number of subjects: 17
Study 31911074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent aerobic exercise (IAE) for 6 weeks
Number of subjects: 36
Study 31911074 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 29745627 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindfolded balance training (BBT) for two weeks
Number of subjects: 16
Study 29745627 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (PT) for two weeks
Number of subjects: 16
Study 28583242 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand files
Number of subjects: 110
Study 28583242 — intervention group
Group type: COMPARATOR
Intervention: Revo‐S rotary instruments
Number of subjects: 110
Study 25123562 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate and elcatonin (combined group, n = 23)
Number of subjects: 45
Study 25123562 — intervention group
Group type: COMPARATOR
Intervention: Risedronate alone (risedronate group, n = 22)
Number of subjects: 45
Study 25123562 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (risedronate and elcatonin; risedronate alone)
Number of subjects: 45
Study 24204744 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI‐559 (live attenuated intranasal vaccine)
Number of subjects: 0
Study 24204744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21914136 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (40 mg for 6 weeks)
Number of subjects: 28
Study 21914136 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 6 weeks)
Number of subjects: 28
Study 19916693 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization in external rotation (ER)
Number of subjects: 55
Study 19916693 — intervention group
Group type: COMPARATOR
Intervention: Immobilization in internal rotation (IR)
Number of subjects: 55
Study 16407639 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oral sustained‐release theophylline plus budesonide (200 microg b.i.d.)
Number of subjects: 90
Study 16407639 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg montelukast plus budesonide (200 microg b.i.d.)
Number of subjects: 90
Study 16407639 — intervention group
Group type: COMPARATOR
Intervention: Double dose of inhaled budesonide (400 microg b.i.d.)
Number of subjects: 90
Study 14525750 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized ED discharge instructions with National Highway Traffic Safety Administration recommendations for motor vehicle CRDs
Number of subjects: 110
Study 14525750 — intervention group
Group type: COMPARATOR
Intervention: CDIs without the recommendations
Number of subjects: 110
Study 10601787 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec varnish (1% chlorhexidine and 1% thymol)
Number of subjects: 65
Study 10601787 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnishes (Fluor Protector and Duraphat)
Number of subjects: 65
Study 10601787 — intervention group
Group type: COMPARATOR
Intervention: Thymol varnish
Number of subjects: 65
Study 9170417 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute febrile infection (HIV-seropositive patients with pneumonia)
Number of subjects: 45
Study 9170417 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute myeloid leukemia with afebrile neutropenia from chemotherapy
Number of subjects: 45
Study 9170417 — intervention group
Group type: COMPARATOR
Intervention: Persistent neutropenia (HIV-seropositive individuals)
Number of subjects: 45
Study 9170417 — intervention group
Group type: COMPARATOR
Intervention: Pneumonia (HIV-seronegative patients)
Number of subjects: 45
Study 1439640 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic protamine administration (group A)
Number of subjects: 32
Study 1439640 — intervention group
Group type: COMPARATOR
Intervention: Intravenous protamine administration (group V)
Number of subjects: 32
Study 2432555 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto increment pacing
Number of subjects: 32